These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 18990031)
1. Outcome of interval debulking in advanced ovarian cancer patients. Suprasert P; Tiyanon J; Kietpeerakool C Asian Pac J Cancer Prev; 2008; 9(3):519-24. PubMed ID: 18990031 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery. Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766 [TBL] [Abstract][Full Text] [Related]
3. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Ren B; Guo W; Chen X J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779 [TBL] [Abstract][Full Text] [Related]
4. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Chang SJ; Bristow RE; Ryu HS Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983 [TBL] [Abstract][Full Text] [Related]
5. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527 [TBL] [Abstract][Full Text] [Related]
6. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Aletti GD; Dowdy SC; Gostout BS; Jones MB; Stanhope CR; Wilson TO; Podratz KC; Cliby WA Obstet Gynecol; 2006 Jan; 107(1):77-85. PubMed ID: 16394043 [TBL] [Abstract][Full Text] [Related]
7. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery. Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332 [TBL] [Abstract][Full Text] [Related]
8. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy. Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676 [TBL] [Abstract][Full Text] [Related]
9. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Chen X Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927 [TBL] [Abstract][Full Text] [Related]
10. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score. da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830 [TBL] [Abstract][Full Text] [Related]
11. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response. Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067 [TBL] [Abstract][Full Text] [Related]
12. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer. Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088 [TBL] [Abstract][Full Text] [Related]
13. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy. Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP Oncology; 2015; 89(3):159-66. PubMed ID: 25968072 [TBL] [Abstract][Full Text] [Related]
14. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction]. Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089 [TBL] [Abstract][Full Text] [Related]
15. The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer. Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I Int J Gynecol Cancer; 2010 May; 20(4):542-51. PubMed ID: 20686373 [TBL] [Abstract][Full Text] [Related]
16. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Melamed A; Nitecki R; Boruta DM; Del Carmen MG; Clark RM; Growdon WB; Goodman A; Schorge JO; Rauh-Hain JA Obstet Gynecol; 2017 May; 129(5):861-869. PubMed ID: 28383367 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480 [TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer. Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897 [TBL] [Abstract][Full Text] [Related]
19. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250 [TBL] [Abstract][Full Text] [Related]